drugset / Trial / NCT04176718
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Phase 2
Active not recruiting
44 enrolled
Andrew Yee, MD
Amgen · collabJanssen Research & Development, LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or previous treatment resistant Multiple Myeloma. This research study involves two study drugs and two standard of care drugs. * The names of the study drugs involved in this study are: * Carfilzomib * Daratumumab * The names of the standard of care drugs involved in this study are: * Dexamethasone * Pomalidomide
Timeline
- Start
- 2020-05-18
- Primary completion
- 2027-05
- Completion
- 2028-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carfilzomib | Other / unclassified | 56 mg/m2 | Intravenous |
| Subject | Daratumumab | Monoclonal antibody | — | Intravenous |
| Background | Dexamethasone | Small molecule | — | Oral |
| Background | Pomalidomide | Other / unclassified | — | Oral |